Project Grant R44NS137901
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$2.1M
Federal Agency
National Institute of Neurological Disorders and Stroke
Awardee
Neurodex Inc. (CK9RG13HMKN5)
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Arlington, MA 02474, USA
Similar Awards
This Project Grant award, valued at $1,106,142 and effective September 1, 2024 through July 31, 2029, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The primary objective is to identify mechanisms of neurofilament regulation and turnover in amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disorder. Key activities...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to assess Pison Technology's neural biosensor as a digital biomarker for characterizing disease progression in amyotrophic lateral sclerosis (ALS). The $459,097 award will fund the development of a wearable device that can remotely monitor physiological data from ALS patients, enabling...
The federal Project Grant award of $1,499,212.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 "Extramural Research Programs in the Neurosciences and Neurological Disorders" supports the development of a novel oral, brain-penetrant therapeutic for amyotrophic lateral sclerosis (ALS) disease by Aquinnah Pharmaceuticals, Inc. The project aims to advance the manufacturing, IND-enabling studies, and a pre-IND meeting with the FDA for this...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to develop a novel cellular model for investigating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will directly convert patient-derived fibroblasts into neurons, preserving the epigenetic age of the starting cells, in order to...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $460,625 to the University of Massachusetts Medical School to investigate the role of the deubiquitylation pathway in regulating TDP-43 pathology associated with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The 2-year project will use mouse...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders provides $532,381 to Emory University to comprehensively investigate the molecular mechanisms underlying the role of the KIF5A gene variant KIF5ADE27 in the pathogenesis of amyotrophic lateral sclerosis (ALS). The key research objectives include: 1) determining the gain-of-function effects of KIF5ADE27...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $251,250 to the University of Massachusetts Medical School to investigate the role of TDP-43 dysfunction and its impact on innate immune pathways and microglial function in models of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The project aims...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to develop novel biomarkers for tracking plexiform neurofibroma tumor burden in individuals with neurofibromatosis type 1 (NF1). The $734,542 award will be used to perform analytical validation studies of candidate biomarker signatures, specifically...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $2,307,075 to The Leland Stanford Junior University (Stanford University) to support research aimed at defining novel mechanisms of neurodegenerative diseases and developing new therapeutic strategies. The key activities include: Using a combination of yeast and human genetics to...